Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses

E. Farah, Maurice E Sarano, A. Vahanian, J. P. Houlegatte, A. Boubaker, Veronique Lee Roger, J. Acar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Thromboembolism, valve thrombosis and haemorrhagic events have been compared in 356 Starr-Edwards (SE) 1260, 133 Bjork-Shiley (BS), and 178 aortic bioprostheses operated upon between 1968 and 1982, and reviewed by the same group with less than 2% of patients lost to follow-up. Expressed in actuarial rate at 7 years the percentage of patients free of thromboembolism event is 87% for SE, 86% for BS, 94% for bioprostheses; the linearized rate is 2.9%/patient/year for SE, 2.2 for BS, 1.9 for bioprostheses (NS). Valve thrombosis was not observed in bioprostheses; 97.9% of patients with mechanical valves were free of valve thrombosis at 6.5 years. Haemorrhagic risk was lower with bioprostheses than with mechanical valves 0.2% patient/year vs 2.33 (P < 0.005). The most important factor influencing thromboembolic and haemorrhagic risks is the quality of anticoagulant therapy. Other contributing factors are the date of the operation and associated mitral disease.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalEuropean Heart Journal
Volume5
Issue numberSUPPL. D
StatePublished - 1984
Externally publishedYes

Fingerprint

Bioprosthesis
Prostheses and Implants
Thrombosis
Thromboembolism
Lost to Follow-Up
Anticoagulants

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Farah, E., Sarano, M. E., Vahanian, A., Houlegatte, J. P., Boubaker, A., Roger, V. L., & Acar, J. (1984). Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses. European Heart Journal, 5(SUPPL. D), 43-47.

Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses. / Farah, E.; Sarano, Maurice E; Vahanian, A.; Houlegatte, J. P.; Boubaker, A.; Roger, Veronique Lee; Acar, J.

In: European Heart Journal, Vol. 5, No. SUPPL. D, 1984, p. 43-47.

Research output: Contribution to journalArticle

Farah, E, Sarano, ME, Vahanian, A, Houlegatte, JP, Boubaker, A, Roger, VL & Acar, J 1984, 'Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses', European Heart Journal, vol. 5, no. SUPPL. D, pp. 43-47.
Farah, E. ; Sarano, Maurice E ; Vahanian, A. ; Houlegatte, J. P. ; Boubaker, A. ; Roger, Veronique Lee ; Acar, J. / Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses. In: European Heart Journal. 1984 ; Vol. 5, No. SUPPL. D. pp. 43-47.
@article{618145dcdb7040279d7e7569552ba18d,
title = "Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses",
abstract = "Thromboembolism, valve thrombosis and haemorrhagic events have been compared in 356 Starr-Edwards (SE) 1260, 133 Bjork-Shiley (BS), and 178 aortic bioprostheses operated upon between 1968 and 1982, and reviewed by the same group with less than 2{\%} of patients lost to follow-up. Expressed in actuarial rate at 7 years the percentage of patients free of thromboembolism event is 87{\%} for SE, 86{\%} for BS, 94{\%} for bioprostheses; the linearized rate is 2.9{\%}/patient/year for SE, 2.2 for BS, 1.9 for bioprostheses (NS). Valve thrombosis was not observed in bioprostheses; 97.9{\%} of patients with mechanical valves were free of valve thrombosis at 6.5 years. Haemorrhagic risk was lower with bioprostheses than with mechanical valves 0.2{\%} patient/year vs 2.33 (P < 0.005). The most important factor influencing thromboembolic and haemorrhagic risks is the quality of anticoagulant therapy. Other contributing factors are the date of the operation and associated mitral disease.",
author = "E. Farah and Sarano, {Maurice E} and A. Vahanian and Houlegatte, {J. P.} and A. Boubaker and Roger, {Veronique Lee} and J. Acar",
year = "1984",
language = "English (US)",
volume = "5",
pages = "43--47",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "SUPPL. D",

}

TY - JOUR

T1 - Thromboembolic and haemorrhagic risk in mechanical and biological aortic prostheses

AU - Farah, E.

AU - Sarano, Maurice E

AU - Vahanian, A.

AU - Houlegatte, J. P.

AU - Boubaker, A.

AU - Roger, Veronique Lee

AU - Acar, J.

PY - 1984

Y1 - 1984

N2 - Thromboembolism, valve thrombosis and haemorrhagic events have been compared in 356 Starr-Edwards (SE) 1260, 133 Bjork-Shiley (BS), and 178 aortic bioprostheses operated upon between 1968 and 1982, and reviewed by the same group with less than 2% of patients lost to follow-up. Expressed in actuarial rate at 7 years the percentage of patients free of thromboembolism event is 87% for SE, 86% for BS, 94% for bioprostheses; the linearized rate is 2.9%/patient/year for SE, 2.2 for BS, 1.9 for bioprostheses (NS). Valve thrombosis was not observed in bioprostheses; 97.9% of patients with mechanical valves were free of valve thrombosis at 6.5 years. Haemorrhagic risk was lower with bioprostheses than with mechanical valves 0.2% patient/year vs 2.33 (P < 0.005). The most important factor influencing thromboembolic and haemorrhagic risks is the quality of anticoagulant therapy. Other contributing factors are the date of the operation and associated mitral disease.

AB - Thromboembolism, valve thrombosis and haemorrhagic events have been compared in 356 Starr-Edwards (SE) 1260, 133 Bjork-Shiley (BS), and 178 aortic bioprostheses operated upon between 1968 and 1982, and reviewed by the same group with less than 2% of patients lost to follow-up. Expressed in actuarial rate at 7 years the percentage of patients free of thromboembolism event is 87% for SE, 86% for BS, 94% for bioprostheses; the linearized rate is 2.9%/patient/year for SE, 2.2 for BS, 1.9 for bioprostheses (NS). Valve thrombosis was not observed in bioprostheses; 97.9% of patients with mechanical valves were free of valve thrombosis at 6.5 years. Haemorrhagic risk was lower with bioprostheses than with mechanical valves 0.2% patient/year vs 2.33 (P < 0.005). The most important factor influencing thromboembolic and haemorrhagic risks is the quality of anticoagulant therapy. Other contributing factors are the date of the operation and associated mitral disease.

UR - http://www.scopus.com/inward/record.url?scp=0021720513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021720513&partnerID=8YFLogxK

M3 - Article

C2 - 6519101

AN - SCOPUS:0021720513

VL - 5

SP - 43

EP - 47

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - SUPPL. D

ER -